Adherence to antiemetic guidelines in patients with malignant glioma: A quality improvement project to translate evidence into practice

Supportive Care in Cancer

Volumn 22, Issue 7, 2014, Pages 1897-1905

  Affronti, Mary Lou ^a,b   Schneider, Susan M ^a   Herndon II, James E ^a   Schlundt, Susan ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiemetic guidelines; Chemotherapy; Chemotherapy induced nausea and vomiting; Emesis; Evidence based practice; Gliomas; Nausea; Supportive care

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; DEXAMETHASONE; IRINOTECAN; METHOTREXATE; PALONOSETRON; TEMOZOLOMIDE;

ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; EVIDENCE BASED PRACTICE; GLIOBLASTOMA; HUMAN; INCIDENCE; MEDICATION COMPLIANCE; NAUSEA AND VOMITING; PRACTICE GUIDELINE; PREMEDICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DEXAMETHASONE; FEMALE; GLIOBLASTOMA; HUMANS; ISOQUINOLINES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUALITY OF LIFE; QUINUCLIDINES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; VOMITING;

EID: 84902373927     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2136-0     Document Type: Article

References (35)

1. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24(16):2563-2569. doi:10.1200/JCO.2005.04.5963 (Pubitemid 46630635)
2. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4): 219-227. doi:10.1007/s00520-004-0710-6 (Pubitemid 40576508)
3. Hawkins R, Grunberg S (2009) Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. Clin J Oncol Nurs 13(1):54-64. doi:10.1188/09.CJON.54-64
4. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482-2494. doi:10.1056/NEJMra0706547
5. Wickham R (2010) Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. J Support Oncol 8(2 Suppl 1):10-15
6. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253-1259. doi:10.1158/1078-0432.CCR-06-2309 (Pubitemid 46424067)
7. Affronti ML, Brickhouse A, Marcello J, Herndon J, Reardon DA, Desjardins A, Vredenburgh J (2009) Phase II single arm trial of palonosetron (PALO) for the prevention of acute and delayed chemotherapy induced nausea and vomiting (CINV) in malignant glioma (MG) patients receiving irinotecan in combination with bevacizumab. In: Society of Neuro-Oncology Annual Meeting. J Neuro-Oncol 5:656. doi:10.1215/15228517-2009- 034272.pub2
8. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090-3098. doi:10.1002/cncr.11433 (Pubitemid 36676265)
9. Chung SK, Ahn MJ, Yoo JY, Choi M, Hyang N, Woo SR, Kim SS, Kim SA, Oh EG (2011) Implementation of best practice for chemotherapy-induced nausea and vomiting in an acute care setting. Int J Evid Based Healthc 9(1):32-38. doi:10.1111/j.1744-1609.2010.00198.x
10. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261-2268. doi:10.1002/cncr.20230 (Pubitemid 38580348)
11. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971-2994 (Pubitemid 29415258)
12. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13(2):85-96. doi:10.1007/s00520-004-0699-x (Pubitemid 40558163)
13. Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C, Dicato M (2005) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):97-103. doi:10.1007/s00520-004-0701-7 (Pubitemid 40558164)
14. Likun Z, Xiang J, Yi B, Xin D, Tao ZL (2011) A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 16(2):207-216. doi:10.1634/theoncologist.2010-0198
15. Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 19(6):823-832. doi:10.1007/s00520-010- 0908-8
16. Barbour SY, Morrow GR, Ahmed G, Ballinari MD, Cox TD, Schwartzberg LS (2011) Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). In: American Society of Clinical Oncology. Journal of Clinical Oncology 15: p 572
17. (NCCN) (2011, 2012) National Comprehensive Cancers Network: clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician- gls/f-guidelines.asp. 2011, 2012
18. Rozzi A, Nardoni C, Corona M, Restuccia MR, Fabi A, Bria E, Minniti G, Lanzetta G (2011) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support Care Cancer 19(5):697-701. doi:10.1007/s00520-010-0893-y
19. Wickham R (2004) Management of intractable nausea and vomiting. Clin J Oncol Nurs 8(1):91-94. doi:10.1188/04.CJON.89-95
20. Booth CM, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W, Trudeau M, Petrella T (2007) Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 5(8):374-380 (Pubitemid 47559694)
21. Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21(7):1373-1378 (Pubitemid 46606418)
22. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR (1999) Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458-1465 (Pubitemid 29493800)
23. Roila F (2004) Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 12(6):446-453. doi:10.1007/s00520-003-0553-6
24. Brearley SG, Clements CV, Molassiotis A (2008) A review of patient self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer 16(11):1213-1229. doi:10.1007/s00520-008-0428-y
25. Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Cancer 98(3): 645-655. doi:10.1002/cncr.11540
26. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The Functional Assessment of Cancer Therapy (FACT) scale.Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75(5):1151-1161
27. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570-579 (Pubitemid 23071057)
28. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to deriveminimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24(6):547-561 (Pubitemid 36120443)
29. Grunberg SM, Aapro, M.S (2012) Education Session on Antiemetics: Current standards, emerging approaches, and persistent gaps. In: American Society of Clinical Oncology Annual Meeting
30. Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20(1):141-147. doi:10.1007/s00520-010-1079-3
31. Farrell C, Brearley SG, Pilling M, Molassiotis A (2013) The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life. Support Care Cancer 21(1):59-66. doi:10.1007/s00520-012-1493-9
32. Tendas A, Sollazzo F, Niscola P, Cupelli L, Mauroni MR, D'Apolito A, Pilozzi V, Cacciaraichi S, Viggiani C, Pignatelli AC, Annibali O, Mengarelli A, Dentamaro T, de Fabritiis P, Arcese W (2013) Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score. Support Care Cancer 21(1):5-6. doi:10.1007/s00520-012-1550-4
33. Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW (2000) Effects of computerized physician order entry on prescribing practices. Arch Intern Med 160(18):2741-2747
34. Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16(2):771-778 (Pubitemid 28135627)
35. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15(1):116-123